Pulse Biosciences outlined its progress with nanosecond pulsed field ablation technology during a presentation at the Bank of America Global Healthcare Conference on May 13.
Chief Executive Paul LaViolette addressed attendees alongside moderator Dan Lundquist. He described the company's exclusive focus on nanosecond pulsed field ablation, which triggers regulated cell death through a novel energy mechanism. LaViolette emphasized ongoing clinical trials and the pursuit of large patient populations in multiple ablation markets.
